Clinical Cancer Research Grants Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lerebours, F.
Right arrow Articles by Lidereau, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lerebours, F.
Right arrow Articles by Lidereau, R.
Clinical Cancer Research Vol. 9, 4184-4189, September 15, 2003
© 2003 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Two Prognostic Groups of Inflammatory Breast Cancer Have Distinct Genotypes1

Florence Lerebours2, Philippe Bertheau, Ivan Bieche, Louis-François Plassa, Marie-Helene Champeme, Kamel Hacene, Christine Toulas, Marc Espie, Michel Marty and Rosette Lidereau

Institut National de la Santé et de la Recherche Médicale E0017/Oncogénétique, F-92211 St-Cloud [F. L., I. B., M. H. C., K. H., R. L.]; Services de Pathologie, Biochimie and Service d’Oncologie Médicale, Hôpital Saint-Louis, Paris [F. L., P. B., L. F. P., M. E.]; Direction de la Recherche Therapeutique, Institut Gustave Roussy, Villejuif [M. M.]; and Laboratoire de Biologie Moleculaire, Institut Claudius Regaud, Toulouse [C. T.], France

Purpose: The prognosis of inflammatory breast cancer (IBC) remains poor despite the use of multimodality treatments, with a 10-year survival rate of not >30%. Clinicopathological and biological predictors of outcome are inadequate in this setting. Analysis of loss of heterozygosity (LOH) can provide a molecular portrait of the genetic alterations underlying stepwise cancer progression. We tested the value of LOH patterns as diagnostic and prognostic markers in IBC.

Experimental design: In a previous study of 64 patients with IBC who were treated homogeneously between 1988 and 1999, we determined LOH frequencies at 71 loci located in 20 chromosomal regions associated with primary breast cancer. Six of these regions bore alterations that were less frequent in non-IBC. In the present study, we sought correlations between these molecular data and the clinicopathological features and clinical outcome of the same 64 patients.

Results: With the exception of stage IV disease, extensive breast inflammation at first clinical examination was the main factor associated with poor outcome (P = 0.00065 versus localized inflammation). The overall frequency of LOH was also higher in this group (P = 0.000073). LOH patterns differed between patients with localized and extensive breast inflammation.

Conclusion: Patients with IBC can be separated into two major prognostic groups on the basis of initial clinical signs, which appear to be subtended by different molecular alterations.




This article has been cited by other articles:


Home page
Cancer Res.Home page
A. Aggarwal, S. H. Leong, C. Lee, O. L. Kon, and P. Tan
Wavelet Transformations of Tumor Expression Profiles Reveals a Pervasive Genome-Wide Imprinting of Aneuploidy on the Cancer Transcriptome
Cancer Res., January 1, 2005; 65(1): 186 - 194.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.